Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals reports developments across its critical care and targeted oncology business, including activity at majority-owned subsidiary Citius Oncology. The company’s recurring updates center on LYMPHIR (denileukin diftitox-cxdl), an engineered IL-2 diphtheria toxin fusion protein approved for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.
Company news also covers LYMPHIR commercialization, U.S. launch progress, international access through Named Patient Programs, and investigator-initiated oncology studies involving gynecologic cancers and diffuse large B-cell lymphoma. Capital updates include registered direct offerings, warrant issuances, non-dilutive funding and other financing actions that support product commercialization and development programs.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that the FDA has provided feedback on its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) aimed at treating acute respiratory distress syndrome (ARDS) in COVID-19 patients. The FDA suggested that Citius could apply for fast track designation and outlined the chemistry, manufacturing, and control (CMC) requirements necessary for upcoming trials. The company plans to initiate an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP) following the FDA's guidance.
Citius Pharmaceuticals (Nasdaq: CTXR) announced that CEO Myron Holubiak will present at the Life Sciences Investor Forum on June 25, 2020, at 11:00 AM ET. The presentation will provide updates on the Company’s ongoing Phase 3 trial for Mino-Lok® and the potential licensing of a novel stem cell therapy for ARDS in COVID-19 patients. Investors can participate and ask questions during the event, which will also be available via archived webcast.